Williams, Dylan;
Bandres-Ciga, Sara;
Heilbron, Karl;
Hinds, David;
Noyce, Alastair;
The 23andMe Research Team;
The International Parkinson's Disease Genomics Consortium;
(2020)
Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.
Annals of Neurology
, 88
(5)
pp. 1043-1047.
10.1002/ana.25880.
Preview |
Text
Annals of Neurology - 2020 - Williams.pdf - Published Version Download (201kB) | Preview |
Abstract
Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid-lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein-A5 or Apolipoprotein-C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020;88:1043–1047
Archive Staff Only
 |
View Item |
